These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27308826)

  • 1. Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind, Randomized Controlled Trial.
    Koppitz M; Eschenburg C; Salzmann E; Rosewich M; Schubert R; Zielen S
    PLoS One; 2016; 11(6):e0156999. PubMed ID: 27308826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
    Dal Negro RW; Visconti M; Turco P
    Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
    van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
    J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial.
    Herrero-Cortina B; Alcaraz V; Vilaró J; Torres A; Polverino E
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):281-289. PubMed ID: 29878856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: A randomized, placebo-controlled, small cohort, cross-over study.
    Ohbayashi H; Setoguchi Y; Fukuchi Y; Shibata K; Sakata Y; Arai T
    Pulm Pharmacol Ther; 2016 Apr; 37():73-80. PubMed ID: 26952317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.
    Watz H; Mistry SJ; Lazaar AL;
    Pulm Pharmacol Ther; 2013 Oct; 26(5):588-95. PubMed ID: 23701917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of doxycycline on local and systemic inflammation in stable COPD patients, a randomized clinical trial.
    Prins HJ; Daniels JM; Lindeman JH; Lutter R; Boersma WG
    Respir Med; 2016 Jan; 110():46-52. PubMed ID: 26616678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS).
    Celli B; Halpin D; Hepburn R; Byrne N; Keating ET; Goldman M
    Respir Med; 2003 Jan; 97 Suppl A():S35-43. PubMed ID: 12564609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS; Gross NJ; Levine B; Kerwin EM; Rinehart M; Denis-Mize K;
    Clin Ther; 2007 Oct; 29(10):2167-78. PubMed ID: 18042473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD).
    Grootendorst DC; Gauw SA; Benschop N; Sterk PJ; Hiemstra PS; Rabe KF
    Pulm Pharmacol Ther; 2003; 16(6):341-7. PubMed ID: 14580925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
    Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS
    Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.
    Greulich T; Hohlfeld JM; Neuser P; Lueer K; Klemmer A; Schade-Brittinger C; Harnisch S; Garn H; Renz H; Homburg U; Renz J; Kirsten A; Pedersen F; Müller M; Vogelmeier CF; Watz H
    Respir Res; 2018 Apr; 19(1):55. PubMed ID: 29615049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.